Cuộc họp công bố kết quả kinh doanh Quý 3/2026 của Neuronetics (STIM): Mở rộng biên lợi nhuận và EBITDA dương
Cuộc họp công bố kết quả kinh doanh quý 3 năm 2026 của Neuronetics: doanh thu tăng 12,5% lên 42 triệu USD, biên lợi nhuận gộp đạt 52,2%, và định hướng cả năm duy trì ở mức 160-164 triệu USD.
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.